Positron emission mammography: Initial clinical results

被引:54
作者
Levine, EA
Freimanis, RI
Perrier, ND
Morton, K
Lesko, NM
Bergman, S
Geisinger, KR
Williams, RC
Sharpe, C
Zavarzin, V
Weinberg, IN
Stepanov, PY
Beylin, D
Lauckner, K
Doss, M
Lovelace, J
Adler, LP
机构
[1] Wake Forest Univ, Sch Med, Dept Radiol, Winston Salem, NC USA
[2] Wake Forest Univ, Sch Med, Dept Pathol, Winston Salem, NC USA
[3] PEM Technol Inc, Bethesda, MD USA
[4] Seleon GmbH, Freiburg, Germany
[5] Fox Chase Canc Ctr, Dept Nucl Med, Philadelphia, PA USA
[6] Wake Forest Univ, Sch Med, Surg Oncol Serv, Dept Surg, Winston Salem, NC 27157 USA
关键词
mammography; breast; imaging; PET; cancer; diagnosis;
D O I
10.1245/ASO.2003.03.047
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Evaluation of high-risk mammograms represents an enormous clinical challenge. Functional breast imaging coupled with mammography (positron emission mammography [PEM]) could improve imaging of such lesions. A prospective study was performed using PEM in women scheduled for stereotactic breast biopsy. Methods: Patients were recruited from the surgical clinic. Patients were injected with 10 mCi of 2-[F-18] fluorodeoxyglucose. One hour later, patients were positioned on the stereotactic biopsy table, imaged with a PEM scanner, and a stereotactic biopsy was performed. Imaging was reviewed and compared with pathologic results. Results: There were 18 lesions in 16 patients. PEM images were analyzed by drawing a region of interest at the biopsy site and comparing the count density in the region of interest with the background. A lesion-to-background ratio >2.5 appeared to be a robust indicator of malignancy and yielded a sensitivity of 86%, specificity of 91%, and overall diagnostic accuracy of 89%. No adverse events were associated with the PEM imaging. Conclusions: The data show that PEM is safe, feasible, and has an encouraging accuracy rate in this-initial experience. Lesion-to-background ratios >2.5 were found to be a useful threshold value for identifying positive (malignant) results. This study supports the further development of PEM.
引用
收藏
页码:86 / 91
页数:6
相关论文
共 14 条
[1]   EVALUATION OF BREAST MASSES AND AXILLARY LYMPH-NODES WITH [F-18] 2-DEOXY-2-FLUORO-D-GLUCOSE PET [J].
ADLER, LP ;
CROWE, JP ;
ALKAISI, NK ;
SUNSHINE, JL .
RADIOLOGY, 1993, 187 (03) :743-750
[2]   Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose:: Use and limitations [J].
Avril, N ;
Rosé, CA ;
Schelling, M ;
Dose, J ;
Kuhn, W ;
Bense, S ;
Weber, W ;
Ziegler, S ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (20) :3495-3502
[3]   Axillary lymph node staging in breast cancer by 2-fluoro-2-deoxy-D-glucose-positron emission tomography: Clinical evaluation and alternative management [J].
Greco, M ;
Crippa, F ;
Agresti, R ;
Seregni, E ;
Gerali, A ;
Giovanazzi, R ;
Micheli, A ;
Asero, S ;
Ferraris, C ;
Gennaro, M ;
Bombardieri, E ;
Cascinelli, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (08) :630-635
[4]  
HENDEE WR, 1988, JAMA-J AM MED ASSOC, V259, P2126
[5]   Variability and accuracy in mammographic interpretation using the American College of Radiology Breast Imaging Reporting and Data System [J].
Kerlikowske, K ;
Grady, D ;
Barclay, J ;
Frankel, SD ;
Ominsky, SH ;
Sickles, EA ;
Ernster, V .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (23) :1801-1809
[6]  
Knopp MV, 1999, JMRI-J MAGN RESON IM, V10, P260, DOI 10.1002/(SICI)1522-2586(199909)10:3<260::AID-JMRI6>3.0.CO
[7]  
2-7
[8]  
Oshida M, 1998, CANCER, V82, P2227, DOI 10.1002/(SICI)1097-0142(19980601)82:11<2227::AID-CNCR18>3.0.CO
[9]  
2-W
[10]   Positron emission tomography using [18F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer [J].
Schelling, M ;
Avril, N ;
Nährig, J ;
Kuhn, W ;
Römer, W ;
Sattler, D ;
Werner, M ;
Dose, J ;
Jänicke, F ;
Graeff, H ;
Schwaiger, M .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1689-1695